Cargando…
Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary
Background: Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of PEG and RBV in treatment of patients chr...
Autores principales: | Odhiambo, Raymond, Chhatwal, Jagpreet, Ferrante, Shannon Allen, El Khoury, Antoine, Elbasha, Elamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia Data Analytics, LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471397/ https://www.ncbi.nlm.nih.gov/pubmed/37664146 http://dx.doi.org/10.36469/9854 |
Ejemplares similares
-
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
por: Ferrante, Shannon Allen, et al.
Publicado: (2013) -
Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012) -
Hepatitis C virus genotype analysis in patients with chronic hepatitis in North Eastern Bulgaria
por: Brady, Zarina, et al.
Publicado: (2019) -
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012) -
Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
por: Husson, Jennifer S., et al.
Publicado: (2017)